# Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

> **NCT06241755** · PHASE3 · RECRUITING · sponsor: **Chengdu CoenBiotech Co., Ltd** · enrollment: 412 (estimated)

## Conditions studied

- Non-Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** BCG for Therapeutic Use
- **DRUG:** BCG for Therapeutic Use

## Key facts

- **NCT ID:** NCT06241755
- **Lead sponsor:** Chengdu CoenBiotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-28
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-09-03
- **Target enrollment:** 412 (ESTIMATED)
- **Last updated:** 2024-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06241755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06241755, "Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06241755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*